Susmed (TSE:4263) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4263 Susmed Inc TSE:4263
75 GF Score
Price 円719.00
GF Value 円847.12
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Susmed Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

TSE:4263
75GF Score
Susmed Inc TSE:4263
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Susmed (TSE:4263) Overvalued in 2026?

Based on GuruFocus' analysis, Susmed stock appears to be undervalued. The current stock price of 円719.00 is trading 15.1% below its estimated GF Value™ of 円847.12. GuruFocus considers Susmed to be Modestly Undervalued.

Key valuation signals for TSE:4263:

  • Dividends Received:
  • GF Value™: 円847.12 vs. price of 円719.00 (15.1% below fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Susmed Business Description

Address 3-7-2 Nihonbashi Honcho, 10th Floor, MFPR Nihonbashi Honcho Building, Chuo-ku, Tokyo, JPN, 103-0023
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
75GF Score

Get the complete analysis for TSE:4263

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円719.00
Price
円847.12
GF Value